QQ客服 官方微博 反馈留言

	Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations
	Miao Longfei; Tian Hongqi
	2019
页码	1-12
关键词	ERK1/2 inhibitors MAPK pathway clinical drug resistant preclinical tumour
ISSN号	1029-2330
DOI	10.1080/1061186X.2019.1648477
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6338995
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Miao Longfei,Tian Hongqi. Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations[J],2019:1-12.
APA	Miao Longfei,&Tian Hongqi.(2019).Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations.,1-12.
MLA	Miao Longfei,et al."Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations".(2019):1-12.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。